Is ALGN a good stock to buy?
Align Technology, Inc. · end-of-day data as of Nov 13, 2026
- PT$194.17 +15.4%
- ConsensusBuy · 17
- P/E vs sector-24.1%
- MAs3 of 4
- MA20×50Golden 6d ago
- MACD1.44
- Sector▲ +15.9%
- Earnings in82d
- P/E24.5x
- RSI61
- Support-2.7%
- Resistance+1.4%
- Off 52w high-16.0%
- Volume0.6x
- Bollingerupper half
- News0.00
- P/E vs own-8.3%
- Trendsideways
- 52w range$130–$200
- ATR+3.6%
- Off ATH-77.2%
- InsidersNone in 90d
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Align Technology a good stock to buy?
Align Technology is strong on 2 of the 5 questions about the business. The price is low: 24.5 times its earnings, below its 3-year median of 30.6 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage some edge
- Economics profitable
- Execution delivers
- Fragility sturdy
- Price below its usual
ALGN sales growth revenue growth
+3%a year, for the last 3 yearsAlign Technology's sales grew 3% a year for 3 years, to $4.03B in fiscal 2025.
ALGN analysts' forecast revenue estimates
+2%the sales they expect next fiscal year, on the lastAnalysts expect Align Technology's sales to grow 2% to $4.13B in fiscal 2026 (12 analysts).
ALGN competitors
pretickt analysis+4%its sales in 12 months, on a year before
Align Technology's sales grew 4% in the 12 months to Sep 30, 2026, faster than GE HealthCare (+2%), slower than Insulet (+26%), Dexcom (+13%) and Zimmer Biomet (+7%).
ALGN sales by business revenue by segment
80%of its sales from Clear AlignerClear Aligner brought Align Technology 80% of its sales in fiscal 2025; Scanners And Services 20%.
ALGN return on capital ROIC
pretickt analysis19%earned before tax on the money invested in itAlign Technology earned 19% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Dexcom 41%, Insulet 30%, GE HealthCare 14% and Zimmer Biomet 7%.
ALGN margin on each sale gross margin
68%left after making the productAlign Technology kept 68% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 67%.
ALGN margin after costs profit margin
15%of sales left after running the businessAlign Technology's operating margin was 15% in the 12 months to Sep 30, 2026, against 17% in fiscal 2022.
ALGN earnings vs estimates
7 of 8quarters above the analysts' estimateAlign Technology beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 28, 2026.
ALGN insider selling
-$1.51Msold, net, by its executives in 12 monthsAlign Technology's executives and directors sold a net $1.51M of shares in the 12 months to Nov 13, 2026; none bought.
ALGN number of employees
-3%fewer people in a yearAlign Technology had 20,290 employees at the end of fiscal 2025, 3% fewer than a year before.
ALGN CEO pay
$19.19Mfor fiscal 2025, 86% of it in stock and optionsAlign Technology paid its CEO $19.19M for fiscal 2025, 86% of it in stock and options.
ALGN financial health Altman Z-score
4.9Altman Z-score, safe above 3Align Technology's Altman Z-score is 4.9 (Nov 13, 2026), above 3, where the safe zone starts.
ALGN biggest customers
under 10%of sales from any one customerNo customer made 10% of Align Technology's sales in fiscal 2025.
ALGN in past recessions
pretickt analysis+3%its sales in the worst oneAlign Technology's sales grew through each of the last 2 US recessions (2008–09 and 2020).
ALGN price vs profit P/E ratio
24.5×a year's earningsAlign Technology's P/E ratio is 24.5 (Nov 13, 2026), below its 3-year median of 30.6.
ALGN price vs competitors
pretickt analysis24.5×a year's earnings, against its competitorsInvestors pay 24.5 times Align Technology's earnings (Nov 13, 2026), more than for GE HealthCare (21.7), less than for Dexcom (32.7), Zimmer Biomet (26.1) and Insulet (24.8).
ALGN analysts' target price target
+15%to their average targetAnalysts' average price target for Align Technology is $194, 15% above the Nov 13, 2026 close of $168.32.
ALGN analyst ratings, 90 days
pretickt analysisEvercore ISI Groupdowngrade Bairddowngrade
In the 90 days to Nov 13, 2026, Evercore ISI Group and Baird downgraded Align Technology.
What is Align Technology's P/E ratio?
Align Technology's P/E ratio is 24.5 (Nov 13, 2026), below its 3-year median of 30.6. Investors pay 24.5 times Align Technology's earnings (Nov 13, 2026), more than for GE HealthCare (21.7), less than for Dexcom (32.7), Zimmer Biomet (26.1) and Insulet (24.8).
Who are Align Technology's biggest competitors?
pretickt compares Align Technology with Insulet, Zimmer Biomet, Dexcom and GE HealthCare. Align Technology's sales grew 4% in the 12 months to Sep 30, 2026, faster than GE HealthCare (+2%), slower than Insulet (+26%), Dexcom (+13%) and Zimmer Biomet (+7%).
Is Align Technology profitable?
Align Technology's operating margin was 15% in the 12 months to Sep 30, 2026, against 17% in fiscal 2022.
Are insiders selling Align Technology stock?
Align Technology's executives and directors sold a net $1.51M of shares in the 12 months to Nov 13, 2026; none bought.
How does Align Technology make money?
Clear Aligner brought Align Technology 80% of its sales in fiscal 2025; Scanners And Services 20%.
How many employees does Align Technology have?
Align Technology had 20,290 employees at the end of fiscal 2025, 3% fewer than a year before.
Who are Align Technology's biggest customers?
No customer made 10% of Align Technology's sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.